The latest news about the diabetes drugs Avandia (rosiglitazone) and its close relative Actos (pioglitazone) is that the FDA had recently asked the manufacturers of these two “glitazones” to add “Black Box” warnings to their labels. Black Box warnings are the most severe warning that can be added to a label: see discussion elsewhere at Black box warning.
This request was disclosed by FDA Commissioner Andrew von Eschenbach in written testimony submitted to a congressional panel at a...
